UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q/A
Amendment No. 1
(Mark One)
 | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2005
 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Transition Period From ___________to _____________
Commission File Number 000-22400
STRATEGIC DIAGNOSTICS INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 56-1581761 | |
| (State or other jurisdiction of | (I.R.S. employer | |
| incorporation or organization) | identification no.) | |
| 111 Pencader Drive | ||
| Newark, Delaware | 19702 | |
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (302) 456-6789
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
| Yes | No |
Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
| Yes | No |
As of June 30, 2005, there were 19,779,898 outstanding shares of the Registrant’s common stock, par value $.01 per share.
STRATEGIC DIAGNOSTICS INC.
EXPLANATORY NOTE
We are amending our quarterly report on Form 10-Q for the period ended June 30, 2005 to restate our consolidated interim financial statements for the three and six month periods ended June 30, 2005 and 2004 and the related disclosures. Please refer to Note 2 to our consolidated interim financial statements included in this amendment on Form 10-Q/A for a further discussion of the restatement. We have also corrected various minor typographical errors in this Form 10-Q/A that occurred during the process of preparing our 2005 second quarter report on Form 10-Q.
Following a series of discussions with the U.S. Securities and Exchange Commission (the “SEC”), the Company determined on December 15, 2005 that it would change its method of accounting for revenue on certain custom antibody arrangements. Accordingly, the Company’s financial statements for the three and six month periods ended June 30, 2005 and 2004 have been restated. The Company changed its revenue recognition policy for custom antibody projects to utilize a methodology whereby revenue is recognized when a project’s specifications have been met and the related antibodies have been shipped, rather than on the percentage-of-completion methodology the Company had used since 1996. The adjustments required to effect this change in accounting impact certain line items as reported in the Consolidated Balance Sheet and Statement of Operations.
The Company also identified an error in the consolidated interim financial statements for the three and six month periods ended June 30, 2005, relating to the determination as to whether the Company had established the technological feasibility of a software project as defined by Statement of Financial Accounting Standard No. 86, “Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise Marketed” whereby costs had been capitalized rather than recognized as research and development expense.
We have amended our annual report on Form 10-K for the year ended December 31, 2004 to restate our consolidated financial statements for the years ended December 31, 2002, 2003 and 2004, and our interim report on Form 10-Q for the three month period ended March 31, 2005 and 2004 and the related disclosures. We have issued consolidated interim financial statements for the quarter ended September 30, 2005 that incorporate the new methodology.
Except as discussed above, we have not modified or updated disclosures presented in the original quarterly report on Form 10-Q, except as required to reflect the effects of the restatement in this Form 10-Q/A. Accordingly, this Form 10-Q/A does not reflect events occurring after the filing of our original Form 10-Q or modify or update those disclosures affected by subsequent events. Information not affected by the restatement is unchanged and reflects the disclosures made at the time of the original filing of the Form 10-Q on August 15, 2005. This Form 10-Q/A should be read in conjunction with our filings made with the Securities and Exchange Commission subsequent to the filing of the original Form 10-K, including any amendments to those filings. The following items in this Form 10-Q/A have been amended as a result of the restatement:
| • | Part I—Item 1—Financial Statements | |
| • | Part I—Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations | |
| • | Part I—Item 4—Controls and Procedures |
Please refer to Note 2 to the accompanying consolidated interim financial statements for additional information on the restatement.
1
STRATEGIC DIAGNOSTICS INC.
INDEX
2
STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)
| June 30, | December 31, | |||||
| 2005 | 2004 | |||||
| (as restated) | (as restated) | |||||
| ASSETS | ||||||
| CURRENT ASSETS: | ||||||
| Cash and cash equivalents | $ | 8,575 | $ | 8,096 | ||
| Receivables, net | 3,694 | 3,107 | ||||
| Inventories | 3,416 | 3,218 | ||||
| Deferred tax asset | 878 | 1,071 | ||||
| Other current assets | 920 | 367 | ||||
| Total current assets | 17,483 | 15,859 | ||||
| Property and equipment, net | 3,478 | 3,605 | ||||
| Other assets | 6 | 2 | ||||
| Deferred tax asset | 8,241 | 8,415 | ||||
| Intangible assets, net | 6,904 | 6,992 | ||||
| Total assets | $ | 36,117 | $ | 34,873 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| CURRENT LIABILITIES: | ||||||
| Accounts payable | $ | 518 | $ | 868 | ||
| Accrued expenses | 1,589 | 1,255 | ||||
| Current portion of long term debt | 211 | 211 | ||||
| Total current liabilities | 2,318 | 2,334 | ||||
| Long-term debt | 667 | 773 | ||||
| Stockholders’ Equity: | ||||||
| Preferred stock, $.01 par value, 20,920,648 shares authorized, no shares issued or outstanding | — | — | ||||
| Common stock, $.01 par value, 35,000,000 shares authorized, 19,779,898 and 19,379,602 issued and | ||||||
| outstanding at June 30, 2005 and December 31, 2004, respectively | 198 | 194 | ||||
| Additional paid-in capital | 37,619 | 36,596 | ||||
| Accumulated deficit | (4,401 | ) | (4,958 | ) | ||
| Deferred compensation | (343 | ) | (206 | ) | ||
| Cumulative translation adjustments | 59 | 140 | ||||
| Total stockholders’ equity | 33,132 | 31,766 | ||||
| Total liabilities and stockholders’ equity | $ | 36,117 | $ | 34,873 | ||
The accompanying notes are an integral part of these statements
3
STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2005 | 2004 | 2005 | 2004 | |||||||||
| (as restated) | (as restated) | (as restated) | (as restated) | |||||||||
| NET REVENUES: | ||||||||||||
| Product related | $ | 6,178 | $ | 5,550 | $ | 12,855 | $ | 11,762 | ||||
| Total net revenues | 6,178 | 5,550 | 12,855 | 11,762 | ||||||||
| OPERATING EXPENSES: | ||||||||||||
| Manufacturing | 2,898 | 2,687 | 5,715 | 5,304 | ||||||||
| Research and development | 851 | 506 | 1,658 | 1,093 | ||||||||
| Selling, general and administrative | 2,290 | 2,144 | 4,765 | 4,672 | ||||||||
| Total operating expenses | 6,039 | 5,337 | 12,138 | 11,069 | ||||||||
| Operating income | 139 | 213 | 117 | 693 | ||||||||
| Interest income (expense), net | 44 | 10 | 71 | 14 | ||||||||
| Income before taxes | 183 | 223 | 788 | 707 | ||||||||
| Income tax expense | 45 | 62 | 231 | 209 | ||||||||
| Net income | 138 | 161 | 557 | 498 | ||||||||
| Basic net income per share | $ | 0.01 | $ | 0.01 | $ | 0.03 | $ | 0.03 | ||||
| Shares used in computing basic | ||||||||||||
| net income per share | 19,728,000 | 19,236,000 | 19,594,000 | 19,236,000 | ||||||||
| Diluted net income per share | $ | 0.01 | $ | 0.01 | $ | 0.03 | $ | 0.03 | ||||
| Shares used in computing diluted | ||||||||||||
| net income per share | 19,810,000 | 19,673,000 | 19,691,000 | 19,718,000 | ||||||||
The accompanying notes are an integral part of these statements
4
STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
| Six Months Ended June 30, | ||||||
| 2005 | 2004 | |||||
| (as restated) | (as restated) | |||||
| Cash Flows from Operating Activities: | ||||||
| Net income | $ | 557 | $ | 498 | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Depreciation and amortization | 457 | 442 | ||||
| Stock compensation expense | 83 | 34 | ||||
| Deferred income tax provision | 231 | 209 | ||||
| (Increase) decrease in: | ||||||
| Receivables | (587 | ) | (34 | ) | ||
| Inventories | (198 | ) | 126 | |||
| Other current assets | (553 | ) | (172 | ) | ||
| Other assets | (4 | ) | — | |||
| Increase (decrease) in: | ||||||
| Accounts payable | (350 | ) | (106 | ) | ||
| Accrued expenses | 334 | 79 | ||||
| Net cash provided by (used in) operating activities | (30 | ) | 1,076 | |||
| Cash Flows from Investing Activities: | ||||||
| Purchase of property and equipment | (237 | ) | (87 | ) | ||
| Net cash used in investing activities | (237 | ) | (87 | ) | ||
| Cash Flows from Financing Activities: | ||||||
| Proceeds from exercise of incentive stock options | 925 | 21 | ||||
| Proceeds from employee stock purchase plan | 8 | 7 | ||||
| Proceeds from issuance of long and short term debt | — | 551 | ||||
| Repayments on financing obligations | (106 | ) | (381 | ) | ||
| Net cash provided by financing activities | 827 | 198 | ||||
| Effect of exchange rate changes on cash | (81 | ) | 14 | |||
| Net increase in cash and cash equivalents | 479 | 1,201 | ||||
| Cash and cash equivalents, beginning of period | 8,096 | 5,158 | ||||
| Cash and cash equivalents, end of period | $ | 8,575 | $ | 6,359 | ||
| Supplemental Cash Flow Disclosure: | ||||||
| Cash paid for taxes | 15 | 5 | ||||
| Cash paid for interest | 23 | 25 | ||||
The accompanying notes are an integral part of these statements
5
STRATEGIC DIAGNOSTICS INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)
(unaudited)
| 1. | DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: |
Business
Strategic Diagnostics Inc. and its subsidiaries (the “Company”) develops and markets biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications. By leveraging its expertise in immunology, proteomics, bio-luminescence, and other bio-reactive technologies with innovative application and production capabilities, the Company is able to provide sophisticated diagnostic testing and immunoreagent systems to a diverse customer base serving multiple vertical markets. The Company also serves the research, human diagnostic and pharmaceutical sectors with a wide range of services, including the production of monoclonal and polyclonal antibodies used in commercialized products offered by leading diagnostic and pharmaceutical companies.
The accompanying unaudited consolidated interim financial statements of the Company have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2004. In the opinion of management, the accompanying consolidated financial statements include all adjustments (all of which are of a normal recurring nature) necessary for a fair presentation of the results of operations.
Certain prior period amounts have been reclassified to conform to the current period’s presentation.
Revenues composed of sales of immunoassay-based test kits and certain antibodies and immunochemical reagents are recognized upon the shipment of the product and transfer of title or when related services are provided. Revenues associated with such products or services are recognized when persuasive evidence of an order exists, shipment of product has occurred or services have been provided, the price is fixed and determinable and, collectibility is probable. Management is required to make judgments based on actual experience about whether or not collectibility is reasonably assured.
The Company enters into contracts related to the production of custom antibodies, which provide for the performance of defined tasks for a fixed price, with delivery of the product upon completion of production. The standard time to complete a project is typically longer than 30 days but less than 12 months and effort is expended over the life of the project. Revenues related to sales of custom antibody projects are recognized when a project’s specifications have been met and the related materials have been shipped.
6
Fees associated with products and services added on to a custom antibody project subsequent to delivery of the initial project are billed monthly and recognized as revenue as the services and other deliverables are provided.
The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. These estimates include those made in connection with assessing the valuation of accounts receivable, inventories, deferred tax assets and percentage of completion on projects for revenue recognition. Actual results could differ from these estimates.
Comprehensive income consists of the following for each period:
| Three Months Ended | Six Months Ended | |||||||||||
| June 30, | June 30, | |||||||||||
| 2005 | 2004 | 2005 | 2004 | |||||||||
| (as restated) | (as restated) | (as restated) | (as restated) | |||||||||
| Net income | $ | 138 | $ | 161 | $ | 557 | $ | 498 | ||||
| Currency translation adjustment | (61 | ) | (10 | ) | (81 | ) | 14 | |||||
| Total comprehensive income | $ | 77 | $ | 151 | $ | 476 | $ | 512 | ||||
| 2. | RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS |
Following a series of discussions with the U.S. Securities and Exchange Commission (the “SEC”), the Company determined on December 15, 2005 that it would change its method of accounting for revenue on certain custom antibody arrangements. Accordingly, the Company’s financial statements for the three and nine month periods ended September 30, 2004 have been restated. The Company changed its revenue recognition policy for custom antibody projects to utilize a methodology whereby revenue is recognized when a project’s specifications have been met and the related antibodies have been shipped, rather than on the percentage-of-completion methodology the Company had used since 1996. The adjustments required to effect this change in accounting primarily impact certain line items as reported in the Consolidated Balance Sheet and Statement of Operations as follows: accounts receivable because of the elimination of unbilled receivables; revenues because they are now recognized when a project is complete; inventories, accrued expenses and manufacturing costs because of the deferral of costs until the completion of a project; and, taxes because of the changes in net income. In addition, the Company identified errors in the 2004 interim financial statements that, although considered to be immaterial have been recorded in the restated 2004 Consolidated Interim Balance Sheet and Statement of Operations. The effect of these changes was an increase of $5,000, $13,000, $87,000 and a decrease of $68,000 in net income for the three months ended June 30, 2005, the three months ended June 30, 2004, the six months ended June 30, 2005 and six months ended June 30, 2004, respectively.
In addition, the Company identified an error in the interim financial statements for the three and six month periods ended June 30, 2005 relating to the determination as to whether the Company had established the technological feasibility of a software development project as defined in Statement of Financial Accounting Standards No. 86, “Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise Marketed,” whereby costs had been capitalized rather than recognized as research and development. Based upon a review of the progress of the project in the fourth quarter of 2005, the Company determined that development issues reported in January 2005 should have led to the conclusion that technological feasibility had not been established. Accordingly, all previously capitalized costs and additional cost incurred to establish technological feasibility should be charged to expense. The effect of this error on net income is a decrease of approximately $56,000 and $137,000 for the three and six month periods ended June 30, 2005, respectively.
7
The following schedules reconcile the amounts originally reported in the Company’s consolidated balance sheets as of June 30, 2005 and December 31, 2004, and the consolidated statements of operations for the three and six month periods ended June 30, 2005 and 2004 to the corresponding amounts in each of these statements (in thousands).
| June 30, | June 30, | ||||||
| 2005 | Adjustments | 2005 | |||||
| (as reported) | (as restated) | ||||||
| Selected Balance Sheet Amounts: | |||||||
| Receivables, net | $ | 4,335 | (641 | ) | 3,694 | ||
| Inventories | $ | 3,266 | 150 | 3,416 | |||
| Other current assets | $ | 861 | 59 | 920 | |||
| Total current assets | $ | 17,915 | (432 | ) | 17,483 | ||
| Property and equipment, net | $ | 3,731 | (253 | ) | 3,478 | ||
| Deferred tax asset | $ | 8,090 | 151 | 8,241 | |||
| Total assets | $ | 36,646 | (529 | ) | 36,117 | ||
| Accrued expenses | $ | 1,869 | (280 | ) | 1,589 | ||
| Total current liabilities | $ | 2,598 | (280 | ) | 2,318 | ||
| Accumulated deficit | $ | (4,152 | ) | (249 | ) | (4,401 | ) |
| Total stockholder’s equity | $ | 33,381 | (249 | ) | 33,132 | ||
| Total liabilities and stockholder’s equity | $ | 36,646 | (529 | ) | 36,117 | ||
| December 31, | December 31, | ||||||
| 2004 | Adjustments | 2004 | |||||
| (as reported) | (as restated) | ||||||
| Selected Balance Sheet Amounts: | |||||||
| Receivables, net | $ | 3,858 | (751 | ) | 3,107 | ||
| Inventories | $ | 3,090 | 128 | 3,218 | |||
| Other current assets | $ | 336 | 31 | 367 | |||
| Total current assets | $ | 16,451 | (592 | ) | 15,859 | ||
| Deferred tax asset | $ | 8,288 | 127 | 8,415 | |||
| Intangible assets, net | $ | 6,996 | (4 | ) | 6,992 | ||
| Total assets | $ | 35,342 | (469 | ) | 34,873 | ||
| Accrued expenses | $ | 1,525 | (270 | ) | 1,255 | ||
| Total current liabilities | $ | 2,604 | (270 | ) | 2,334 | ||
| Accumulated deficit | $ | (4,759 | ) | (199 | ) | (4,958 | ) |
| Total stockholder’s equity | $ | 31,965 | (199 | ) | 31,766 | ||
| Total liabilities and stockholder’s equity | $ | 35,342 | (469 | ) | 34,873 | ||
8
| Three Months Ended | Three Months Ended | ||||||
| June 30, 2005 | Adjustments | June 30, 2005 | |||||
| (as reported) | (as restated) | ||||||
| Selected Statement of Operations Amounts: | |||||||
| Product related revenues | $ | 6,218 | (40 | ) | 6,178 | ||
| Total revenues | $ | 6,218 | (40 | ) | 6,178 | ||
| Manufacturing expenses | $ | 2,931 | (33 | ) | 2,898 | ||
| Research and development | $ | 737 | 114 | 851 | |||
| Selling general and administrative expenses | $ | 2,324 | (34 | ) | 2,290 | ||
| Total operating expenses | $ | 5,992 | 47 | 6,039 | |||
| Operating income (loss) | $ | 226 | (87 | ) | 139 | ||
| Income (loss) before taxes | $ | 270 | (87 | ) | 183 | ||
| Income tax expense (benefit) | $ | 81 | (36 | ) | 45 | ||
| Net income (loss) | $ | 189 | (51 | ) | 138 | ||
| Basic net income (loss) per share applicable to common shareholders | $ | 0.01 | 0.00 | 0.01 | |||
| Diluted net income (loss) per share applicable to common shareholders | $ | 0.01 | 0.00 | 0.01 | |||
| Three Months Ended | Three Months Ended | ||||||
| June 30, 2004 | Adjustments | June 30, 2004 | |||||
| (as reported) | (as restated) | ||||||
| Selected Statement of Operations Amounts: | |||||||
| Product related revenues | $ | 5,420 | 130 | 5,550 | |||
| Total revenues | $ | 5,420 | 130 | 5,550 | |||
| Manufacturing expenses | $ | 2,579 | 108 | 2,687 | |||
| Selling general and administrative expenses | $ | 2,144 | 0 | 2,144 | |||
| Total operating expenses | $ | 5,229 | 108 | 5,337 | |||
| Operating income (loss) | $ | 191 | 22 | 213 | |||
| Income (loss) before taxes | $ | 201 | 22 | 223 | |||
| Income tax expense (benefit) | $ | 53 | 9 | 62 | |||
| Net income (loss) | $ | 148 | 13 | 161 | |||
| Basic net income (loss) per share applicable to common shareholders | $ | 0.01 | 0.00 | 0.01 | |||
| Diluted net income (loss) per share applicable to common shareholders | $ | 0.01 | 0.00 | 0.01 | |||
9
| Six Months Ended | Six Months Ended | ||||||
| June 30, 2005 | Adjustments | June 30, 2005 | |||||
| (as reported) | (as restated) | ||||||
| Selected Statement of Operations Amounts: | |||||||
| Product related revenues | $ | 12,773 | 82 | 12,855 | |||
| Total revenues | $ | 12,773 | 82 | 12,855 | |||
| Manufacturing expenses | $ | 5,832 | (117 | ) | 5,715 | ||
| Research and development | $ | 1,379 | 279 | 1,658 | |||
| Selling general and administrative expenses | $ | 4,766 | (1 | ) | 4,765 | ||
| Total operating expenses | $ | 11,977 | (161 | ) | 12,138 | ||
| Operating income (loss) | $ | 796 | (79 | ) | 717 | ||
| Income (loss) before taxes | $ | 867 | (79 | ) | 788 | ||
| Income tax expense (benefit) | $ | 260 | (29 | ) | 231 | ||
| Net income (loss) | $ | 607 | (50 | ) | 557 | ||
| Basic net income (loss) per share applicable to common shareholders | $ | 0.03 | 0.00 | 0.03 | |||
| Diluted net income (loss) per share applicable to common shareholders | $ | 0.03 | 0.00 | 0.03 | |||
| Six Months Ended | Six Months Ended | ||||||
| June 30, 2004 | Adjustments | June 30, 2004 | |||||
| (as reported) | (as restated) | ||||||
| Selected Statement of Operations Amounts: | |||||||
| Product related revenues | $ | 11,770 | (8 | ) | 11,762 | ||
| Total revenues | $ | 11,770 | (8 | ) | 11,762 | ||
| Manufacturing expenses | $ | 5,201 | 103 | 5,304 | |||
| Selling general and administrative expenses | $ | 4,672 | 0 | 4,672 | |||
| Total operating expenses | $ | 10,966 | 103 | 11,069 | |||
| Operating income (loss) | $ | 804 | (111 | ) | 693 | ||
| Income (loss) before taxes | $ | 818 | (111 | ) | 707 | ||
| Income tax expense (benefit) | $ | 252 | (43 | ) | 209 | ||
| Net income (loss) | $ | 566 | (68 | ) | 498 | ||
| Basic net income (loss) per share applicable to common shareholders | $ | 0.03 | 0.00 | 0.03 | |||
| Diluted net income (loss) per share applicable to common shareholders | $ | 0.03 | 0.00 | 0.03 | |||
Net cash provided by operating activities decreased by $307,000 and net cash used in investing activities decreased by $307,000 for the six months ended June 30, 2005 as a result of the restatement. There was no impact on net cash provided by financing activities for the six months ended June 30, 2005.
There is no impact on net cash provided by operating activities, net cash used in investing activities or on net cash provided by financing activities as reported on the consolidated statements of cash flows for the period ended June 30, 2004.
| 3. | BASIC AND DILUTED INCOME (LOSS) PER SHARE: |
Basic earnings per share (EPS) is computed by dividing net income available for common shareholders by the weighted-average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS, except that the dilutive effect of converting or exercising all potentially dilutive securities is also included in the denominator. The Company’s calculation of diluted EPS includes the dilutive effect of exercising stock options into common shares.
10
As of June 30, 2005, options to purchase 1,821,000 shares of the Company’s common stock were outstanding, with options to purchase approximately 1,205,000 shares exercisable. Listed below are the basic and diluted share calculations.
| Three Months Ended | Six Months Ended | |||||||
| June 30, | June 30, | |||||||
| 2005 | 2004 | 2005 | 2004 | |||||
| Weighted avg. common shares outstanding | 19,727,816 | 19,236,317 | 19,594,497 | 19,235,938 | ||||
| Shares used in computing basic net income per share | 19,727,816 | 19,236,317 | 19,594,497 | 19,235,938 | ||||
| Stock options | 82,368 | 436,613 | 96,099 | 482,111 | ||||
| Shares used in computing diluted net income per share | 19,810,183 | 19,672,930 | 19,690,596 | 19,718,049 | ||||
11
| 4. | STOCK-BASED COMPENSATION |
The Company applies the intrinsic-value-based method to account for its fixed-plan stock options. Compensation expense is recorded on the date of grant only if the current market price of the underlying stock, at that date, exceeded the exercise price. The Company has elected to continue to apply the intrinsic-value-based method of accounting described above, and has adopted only the disclosure requirements of SFAS No. 123, “Accounting for Stock-Based Compensation.” Under the Company’s employee share option plans, the Company grants employee and outside director stock options at an exercise price equal to the fair market value at the date of grant. No compensation expense is recorded with respect to such stock option grants. Compensation expense with respect to stock awards granted is measured based upon the fair value of such awards and is charged to expense over the vesting period.
The following table illustrates the effect on net income and earnings per share if the fair value based method had been applied to all outstanding and unvested awards in each period.
| Three Months Ended | Six Months Ended | |||||||||||
| June 30, | June 30, | |||||||||||
| 2005 | 2004 | 2005 | 2004 | |||||||||
| (as restated) | (as restated) | (as restated) | (as restated) | |||||||||
| Net income | $ | 138 | $ | 161 | $ | 557 | $ | 498 | ||||
| Add: Stock-based employee compensation expense | ||||||||||||
| included in reported net income (loss), net of | ||||||||||||
| related tax effects | 39 | 19 | 59 | 24 | ||||||||
| Deduct: Total stock-based employee | ||||||||||||
| compensation expense determined under fair | ||||||||||||
| value based method for all awards, net of | ||||||||||||
| related tax effects | (211 | ) | (269 | ) | (394 | ) | (512 | ) | ||||
| Net income (loss)—as adjusted | $ | (34 | ) | $ | (89 | ) | $ | 222 | $ | 10 | ||
| Earnings per share: | ||||||||||||
| Basic—as reported | $ | 0.01 | $ | 0.01 | $ | 0.03 | $ | 0.03 | ||||
| Basic—as adjusted | $ | — | $ | — | $ | 0.01 | $ | — | ||||
| Diluted—as reported | $ | 0.01 | $ | 0.01 | $ | 0.03 | $ | 0.02 | ||||
| Diluted—as adjusted | $ | — | $ | — | $ | 0.01 | $ | — | ||||
12
| 5. | INVENTORIES: |
The Company’s inventories are valued at the lower of cost or market. For inventories that consist primarily of test kit components, bulk serum and antibody products, cost is determined using the first in, first out method. For inventories that consist of costs associated with the production of custom antibodies, cost is determined using the specific identification method. At June 30, 2005 and December 31, 2004, inventories consisted of the following:
| June 30, 2005 | December 31, 2004 | |||||
| (as restated) | (as restated) | |||||
| Raw materials | $ | 1,419 | $ | 1,410 | ||
| Work in progress | 628 | 633 | ||||
| Finished goods | 1,369 | 1,175 | ||||
| $ | 3,416 | $ | 3,218 | |||
| 6. | INTANGIBLE ASSETS: |
At June 30, 2005 and December 31, 2004, intangible assets consisted of the following:
| June 30, 2005 | December 31, 2004 | ||||||
| Goodwill | $ | 5,168 | $ | 5,168 | |||
| Other | 3,017 | 3,000 | |||||
| Less-accumulated amortization | (1,281 | ) | (1,176 | ) | |||
| Net intangible assets | $ | 6,904 | $ | 6,992 | |||
| 7. | DEBT: |
On May 5, 2000, the Company entered into a financing agreement with a commercial bank. This agreement provides for a $4,000 term loan, all of which had been paid on or before December 31, 2002, and for up to a $5,000 revolving line of credit, none of which was outstanding and approximately $2,685 of which was available at June 30, 2005, based on eligible assets. The revolving line of credit bears a variable interest rate of between 1.75% and 2.75% over LIBOR depending upon the ratio of the Company’s funded debt to EBITDA, and is subject to a borrowing base determined by the Company’s eligible accounts receivable. The Company’s annual effective rate of interest on this line of credit, taking into account the variable interest rate and LIBOR, was approximately 5.07% at June 30, 2005.
On December 13, 2001, the Company entered into an agreement with a commercial bank to finance the construction of new facilities at its Windham, Maine location. This agreement provided for up to $1,500 in financing, $878 of which was outstanding at June 30, 2005, and is repayable over seven years, with principal payments that began on October 1, 2002. The loan bears a variable interest rate of between 2% and 3% over LIBOR depending upon the ratio of the Company’s funded debt to EBITDA, as defined. Payments are due monthly, with equal amortization of principal payments plus interest. The Company’s annual effective rate of interest on this loan at June 30, 2005 was approximately 5.32% .
13
Under the terms of the above financing, the Company is required to meet certain quarterly financial covenants that included for the first three quarters of 2003 a minimum quick ratio of 2.25 and a minimum tangible net worth ratio of $22,500, which the Company met. Beginning with the fourth quarter of 2003, the original provisions of the loan agreement regarding financial covenants were operative, namely a ratio of EBITDA to current maturities of debt plus interest and cash paid for taxes greater than 1.50 and a ratio of funded debt to EBITDA not to exceed 3.25. The Company was not in compliance with these fourth quarter 2003 covenants at December 31, 2003. In February 2004, the Company amended the terms of the EBITDA covenants with the lender to exclude the impact of up to $3,315 of charges the Company incurred in the fourth quarter 2003, and therefore, the Company met the covenant requirements for the fourth quarter 2003. Under the amended covenant, the Company met all of its financial covenants with respect to this indebtedness at June 30, 2005 and expects that it will be able to meet all of its financial covenants with respect to this indebtedness for the remainder of 2005.
As of June 30, 2005, the outstanding balance on all of the Company’s commercial bank debt was $878. This indebtedness is secured by substantially all of the Company’s assets.
14
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
This Form 10-Q contains certain forward-looking statements reflecting the current expectations of Strategic Diagnostics Inc. and its subsidiaries (“we”, the “Company” or “SDI”). These statements include, among others, statements regarding: the Company’s intentions with respect to future spending on research and development; the development, market acceptance and sales of tests for food-borne pathogens and related growth media; the size and nature of demand in the markets for the Company’s products and related effects on operating results; the need for water quality and toxicity tests; approval and validation by third parties of the Company’s food pathogen tests; the performance of the Company’s testing products; sales of the Company’s antibodies; timing of new product introductions and other information that may be predictive of future operating results; the Company’s ability to reduce operating expenses; and the Company’s ability to improve operating results thus enabling it to meet future loan covenants. In addition, when used in this Form 10-Q, the words “anticipate,” “enable,” “estimate,” “intend,” “expect,” “believe,” “potential,” “may,” “will,” “should,” “project” and similar expressions as they relate to the Company are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers, attraction and retention of management and key employees, adequate supply of raw materials, inability to obtain or delays in obtaining third party approvals, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, the ability to obtain financing and other factors more fully described in the Company’s public filings with the U.S. Securities and Exchange Commission.
Restatement of Consolidated Financial Statements
Following a series of discussions with the SEC, the Company determined on December 15, 2005 that it would change its method of accounting for revenue on certain custom antibody arrangements. Accordingly, the Company’s financial statements for the three and six month periods ended June 30, 2005 and 2004 have been restated. The Company changed its revenue recognition policy for custom antibody projects to utilize a methodology whereby revenue is recognized when a project’s specifications have been met and the related antibodies have been shipped, rather than on the percentage-of-completion methodology the Company had used since 1996. The Company also identified an error in the financial statements for the three and six month periods ended June 30, 2005 related to the determination as to whether the Company had established the technological feasibility of a software project as defined by Statement of Financial Accounting Standard No. 86, “Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise Marketed,” whereby costs had been capitalized rather than expensed as research and development. Please refer to Note 2 to our consolidated interim financial statements for a further discussion of the restatement.
We provide bio-services and industrial bio-detection services. Bio-services include providing custom antibody production services and antibody reagents to the diagnostic, pharmaceutical, bio-medical and academic research and development markets. Industrial bio-detection services include providing test kits for assessing the health, safety and quality of food, water and the environment.
15
Our primary core competency is the development and manufacture of antibodies. Such antibodies are incorporated into test kits manufactured by us for the detection of a wide variety of substances related to food safety and water quality and for use by medical diagnostic and pharmaceutical companies and research institutions.
Our food safety product group includes tests to detect specific traits in genetically engineered plants, tests to detect Genetically Modified (GM) traits in food ingredients and food fractions, tests to detect naturally occurring fungi in grains (mycotoxins) and tests for food pathogens.
Our water quality product group includes tests to detect toxicity in drinking water, industrial process water and wastewater, and tests to detect specific traits in soil and other waste matter for use at environmental remediation projects, hazardous waste operations and other applications.
Our antibody product group provides a wide array of antibodies and antibody services, including hybridoma development, calibrators, antigens and reagents and the production of monoclonal and polyclonal antibodies. Such antibodies are incorporated into test kits we manufacture as described above and diagnostic and therapeutic products, and used in clinical research.
We sell products and services in the food safety, water quality and antibody market categories through our U.S. direct sales force, a network of over 50 distributors in Canada, Mexico, Latin America, Europe and Asia and our corporate partners. These products and services are sold to a wide range of customers including water utilities, food processors, pharmaceutical, biotechnology and diagnostic companies and major biomedical research centers.
Results of Operations
Three Months Ended June 30, 2005 versus June 30, 2004
Revenues for the second quarter of 2005 increased 11.3% to $6.18 million, compared to $5.55 million for the second quarter of 2004. Included in revenues in the second quarter of 2004 was $56,000 of sales associated with certain “catalog” antibody inventories that were written off in the fourth quarter of 2003 and therefore recorded with no associated cost of goods sold. Revenue growth in 2005 continued to be offset by previously anticipated reductions in StarLinkTM test kit sales, which decreased by $43,000 to $233,000 in the second quarter of 2005, compared to the same quarter in 2004.
For the second quarter of 2005, gross profit (defined as total revenues less manufacturing costs) increased 14.5% to $3.28 million, compared to $2.86 million in the second quarter of 2004, and gross margins increased from 51.6% in the second quarter of 2004 to 53.0% in the second quarter of 2005.
Operating expenses for the second quarter of 2005 increased 13.2% to $6.04 million, compared to $5.34 million for the second quarter of 2004, partially due to research expenses incurred of $165,000 related to our investment in the commercialization of new technologies and high throughput production of antibodies and the investment in a software upgrade for the Microtox® test system totaling $114,000.
16
Research and development spending was $851,000, or 13.8% of net revenues, in the second quarter of 2005, compared to $506,000, or 9.1% of net revenues, in the second quarter of 2004. This increase reflects our continued commitment to customer-centric product development.
Selling, general and administrative expenses were $2.29 million in the 2005 quarter, compared to $2.14 million for the same quarter in 2004. Selling, general and administrative expenses for the second quarter of 2004 reflect a benefit related to the recovery of a $100,000 receivable it had written off in 2001. No comparable benefit was recorded for the second quarter of 2005.
We recorded interest income, net of interest expense, of $44,000 in the second quarter of 2005 compared to interest income of $10,000 in the prior year second quarter primarily due to higher levels of invested cash during the 2005 period.
Pre-tax income totaled $183,000 for the second quarter of 2005, compared to pre-tax income of $223,000 for the same period in 2004.
Our effective tax rate of 25% for the second quarter of 2005 is below the federal and state statutory rates primarily due to research and development credits and the utilization of foreign net operating losses not previously benefited.
Net income in the second quarter of 2005 was $138,000, compared to $161,000 for the same period in 2004, or $0.01 per diluted share for each quarter. Diluted shares utilized in these computations were 19,810,000 and 19,673,000 for the second quarter of 2005 and 2004, respectively.
Six Months Ended June 30, 2005 vs. June 30, 2004
For the six months ended June 30, 2005, revenues increased 9.3% to $12.86 million, compared to $11.76 million for the same period in 2004. Included in revenues in the six month period ended June 30, 2004 was $212,000 of sales associated with certain “catalog” antibody inventories that were written-off in the fourth quarter of 2003 with substantially no associated cost of goods sold. StarLink™ test kit sales, as described above, decreased to $405,000 for the six month period ended June 30, 2005, compared to $512,000 for the same period in 2004. Sales of our test kits used in other agriculture applications were also down, primarily due to order pattern. We see the agriculture market becoming very competitive among providers of test methods. This market has not expanded as new product introduction has slowed, and existing applications have seen a decrease in testing demand.
Gross profit for the six months ended June 30, 2004 increased $682,000 compared to the first six months of 2004, from $6.46 million to $7.14 million, and gross margins increased from 54.9% in 2004 to 55.5% in 2005.
For the six months ended June 30, 2005, operating expenses increased 9.9% to $12.14 million, compared to $11.07 million in the same period in 2004, due primarily to research expenses incurred of $297,000 related to our investment in the commercialization of new technologies and high throughput production of antibodies and the investment in a software upgrade for the Microtox® test system totaling $279,000.
17
For the six months ended June 30, 2005, research and development spending was $1.66 million, or 12.9%, of net revenues, compared to $1.09 million, or 9.3%, for the same period in 2004.
Selling, general and administrative expenses were $4.77 million for the six months ended June 30, 2005, compared to $4.67 million for the same period in 2004. Selling, general and administrative expenses for the six month period ended June 30, 2004 included a charge of $100,000 associated with the termination of a distribution reseller agreement for an instrument we determined was not going to be marketable. No comparable charge was recorded for the six months ended June 30, 2005.
We recorded interest income, net of interest expense, of $71,000 for the six months ended June 30, 2005 compared to $14,000 for the six months ended June 30, 2004, due to higher levels of invested cash during the 2005 period.
Pre-tax income totaled $788,000 for the six months ended June 30, 2005, compared to $707,000 for the same period in 2004.
Our effective tax rate of 29% for the six months ended June 30, 2005 is below the federal and state statutory rates primarily due to research and development credits and the utilization of foreign net operating losses not previously benefited.
Net income in the six months ended June 30, 2005 was $557,000, or $0.03 per diluted share, compared to $498,000 for the same period in 2004, or $0.03 per diluted share for same six month period. Diluted shares totaling 19,691,000 and 19,718,000 were used in the computation for the first six months of 2005 and 2004, respectively.
Product Groups
Food Safety Products – Food safety revenues were $1.85 million in the second quarter of 2005, compared to $1.41 million in the second quarter of 2004, an increase of 31.1% . For the six months ended June 30, 2005, food safety revenues were $4.35 million, compared to $3.65 million for the same period in 2004, an increase of 19.4% . Food pathogen test sales in the second quarter of 2005 and the six months ended June 30, 2005 were up 139.0% and 125.0%, respectively, compared to the same periods of 2004. Contributing to the increase in food pathogen test sales in the second quarter of 2005 is the impact of the previously announced exclusive agreement with an international distributor.
Water and Environmental Products – Water and environmental revenues increased 2.8% to $1.63 million for the second quarter of 2005, compared to $1.59 million for the same quarter in 2004, but decreased 6.4% to $2.85 million for the six month period ended June 30, 2005, compared to $3.05 million for the same period in 2004. Although this product group has historically had high attrition, our efforts, including the development of new channels to market, adding new products and adding sales professionals, are beginning to have a positive impact on revenues. This is the first quarter in several years where this product line has seen an increase over prior quarters. The previously announced US Biosystems (now Genapure) initiative was commercially launched to the Florida market in July 2005 to immediate sales.
18
Antibody Products – antibody revenues increased 5.8% to $2.70 million for the second quarter of 2005 compared to $2.55 million for the same quarter in 2004, and increased 11.9% to $5.66 million in the six months ended June 30, 2005, compared to $5.06 million for the same period in the prior year. The increase in the second quarter of 2005 over the same period in 2004 continues the improvement in the business, which saw a steep decline in revenues in the first half of 2004 associated with the completion of several large, one-time customer projects in 2003, and the discontinuation of low margin business early in 2004.
Liquidity and Capital Resources
The net cash used by operating activities of $30,000 for the six months ended June 30, 2005 was primarily the result of cash from operating activities being reduced by increases in current assets. The increase in current assets was primarily the result of the purchase of insurance for the 2005 business year.
Net cash used in investing activities of $237,000 for the six months ended June 30, 2005 was driven by capital expenditures primarily for laboratory and manufacturing equipment related to the Company’s investment in the commercialization of new technologies and high throughput production of antibodies. This compares to net cash used in investing activities of $87,000 for the same period in 2004, which was driven by capital expenditures for the period primarily related to purchases of office and manufacturing equipment.
Net cash provided by financing activities of $827,000 for the six months ended June 30, 2005 was primarily driven by proceeds from the exercise of stock options, which was partially offset by net repayments of outstanding debt. The $198,000 provided by financing activities for the same period in 2004 was primarily the result of acquiring a $551,000 loan to finance our 2004 business insurance program, net of debt repayments.
Our working capital, current assets less current liabilities, increased $1.66 million to $15.19 million at June 30, 2005 from $13.53 million at December 31, 2004, primarily due to the increase in current assets described above. Outstanding debt decreased $106,000 from $984,000 at December 31, 2004 to $878,000 on June 30, 2005, due to scheduled repayments.
On May 5, 2000, we entered into a financing agreement with a commercial bank. This agreement provides for a $4.00 million term loan, all of which had been paid on or before December 31, 2002, and for up to a $5.00 million revolving line of credit, none of which was outstanding and approximately $2.69 million of which was available at June 30, 2005, based on eligible assets.
The revolving line of credit bears a variable interest rate of between 1.75% and 2.75% over LIBOR depending upon the ratio of our funded debt to EBITDA, and is subject to a borrowing base determined by our eligible accounts receivable. Our annual effective rate of interest on this line of credit, taking into account the variable interest rate and LIBOR, was approximately 5.07% at June 30, 2005.
19
On December 13, 2001, we entered into an agreement with a commercial bank to finance the construction of new facilities at our Windham, Maine location. This agreement provided for up to $1.5 million in financing, $878,000 of which was outstanding at June 30, 2005, and is repayable over seven years, with principal payments that began on October 1, 2002. The loan bears a variable interest rate of between 2% and 3% over LIBOR depending upon the ratio of our funded debt to EBITDA. Payments are due monthly, with equal amortization of principal payments plus interest. Our annual effective rate of interest on this loan at June 30, 2005 was approximately 5.32%.
Under the terms of the above financing, we are required to meet certain quarterly financial covenants that include a ratio of EBITDA to current maturities of debt plus interest and cash paid for taxes greater than 1.50 and a ratio of funded debt to EBITDA not to exceed 3.25. We met all of our financial covenants with respect to this indebtedness at June 30, 2005 and expect that we will be able to meet all of our financial covenants with respect to this indebtedness for the remainder of 2005.
For the six months ended June 30, 2005, we satisfied all of our cash requirements from cash provided by operating activities, cash available and on-hand and from the financing agreements described above. At June 30, 2005, we had $667,000 in long-term debt and stockholders’ equity of $33.13 million. Although we have no material commitments for capital expenditures at June 30, 2005, we do anticipate that we may spend approximately $1 million in 2005 to upgrade or expand certain manufacturing, research & development and office equipment and systems that will drive productivity or generate cost savings, and also to introduce automation into certain manufacturing processes that are currently labor intensive.
Based upon our cash on hand, credit facilities, current product sales and the anticipated sales of new products, we believe we have, or have access to, sufficient resources to meet our operating requirements at least through July 2006. Our ability to meet our long-term capital needs will depend on a number of factors, including compliance with existing and new loan covenants, the success of our current and future products, the focus and direction of our research and development programs, competitive and technological advances, future relationships with corporate partners, government regulation, our marketing and distribution strategy, our successful sale of additional common stock and/or our successfully locating and obtaining other financing, and the success of our plan to make future acquisitions. Accordingly, no assurance can be given that we will be able to meet the future liquidity requirements that may arise from these inherent and similar uncertainties.
Non-GAAP Financial Measures
EBITDA measures are presented as we believe this provides investors and our management with additional information to measure our liquidity. EBITDA measures are not a measure of performance under GAAP, and therefore should not be considered in isolation or as a substitute for net income or cash flows from operations. Additionally, our EBITDA calculations may differ from the EBITDA calculations for other companies.
20
The calculation of our EBITDA measure (as discussed above), and the reconciliation of our EBITDA measure to net cash provided by operating activities for the six months ended June 30, 2005 and 2004, respectively, is as follows:
| Six Months Ended June 30, | ||||||
| 2005 | 2004 | |||||
| (as restated) | (as restated) | |||||
| Net cash (used in) provided by operating activities | $ | (30 | ) | $ | 1,076 | |
| Changes in assets and liabilities: | ||||||
| Receivables | 587 | 34 | ||||
| Inventories | 198 | (126) | ||||
| Other current assets | 553 | 172 | ||||
| Other assets | 4 | — | ||||
| Accounts payable | 350 | 106 | ||||
| Accrued expenses | (334) | (79) | ||||
| Stock compensation expense | (83) | (34) | ||||
| Interest income, net | (71) | (14) | ||||
| EBITDA | $ | 1,174 | $ | 1,135 | ||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
We have exposure to changing interest rates, and are currently not engaged in hedging activities. Interest on approximately $878,000 of outstanding indebtedness is at a variable rate of between 2% to 3% over the published London Interbank Offered Rate (LIBOR), based upon our ratio of funded debt to EBITDA, and was 3% over LIBOR on average for the year. At our current level of indebtedness, each 1% change in the variable interest rate will have an effect of $9,000 on our annual interest expense charges.
We conduct operations in United Kingdom. The consolidated financial statements are presented in U.S. dollars and changes in exchange rates between foreign countries and the U.S. dollar will affect the translation of financial results of foreign subsidiaries into U.S. dollars for purposes of recording our consolidated financial results. Historically, the effects of translation have not been material to the consolidated financial results.
21
| Item 4. | Controls and Procedures |
| (a) | Evaluation of Disclosure Controls and Procedures |
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Act of 1934, as amended, as of June 30, 2005, the end of the period covered by the previously issued second quarter of 2005 Form 10-Q. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were functioning effectively as of that date to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our principal executive and financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Following a series of discussions with the U.S. Securities and Exchange Commission, the Company determined on December 15, 2005 that it would change its method of accounting for revenue on certain custom antibody arrangements. Consequently, the Company has reflected the change in its restated results for all periods presented in this Form 10-Q/A. The Company changed its revenue recognition policy for custom antibody projects to utilize a methodology whereby revenue is recognized when a project’s specifications have been met and the related antibodies have been shipped, rather than on the percentage-of-completion methodology the Company had used since 1996. In addition, the Company corrected an error in their 2005 interim financial statements relating to the determination as to whether the Company had established the technological feasibility of a software development project.
The Company’s Chief Executive Officer and Chief Financial Officer have reassessed our disclosure controls and procedures for this Form 10-Q/A. Based on the reassessment, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were therefore not, as of June 30, 2005, effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our principal executive and financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Not withstanding the need to restate previously issued financial statements, we believe that management had reasonable support for its historical method of accounting.
| (b) | Change in Internal Control over Financial Reporting |
No change in the Company’s internal control over financial reporting occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the internal control over financial reporting.
Subsequent to June 30, 2005, management has instituted additional annual and quarterly review procedures for revenue recognition and software capitalization accounting policies to ensure that we continually evaluate such policies and their compliance with generally accepted accounting principles.
22
| ITEM 4. | Submission of Matters to a Vote of Security Holders. |
On May 3, 2005, we held our annual meeting of stockholders. At the annual meeting, the stockholders voted on the election of three directors, each for a two-year term. The voting results at the annual meeting were as follows:
| Name of Nominee | Votes For | Votes Withheld | |||
| Morton Collins | 17,248,955 | 132,071 | |||
| Matthew H. Knight | 17,248,360 | 132,666 | |||
| Grover C. Wrenn | 17,244,388 | 136,638 |
The terms of Richard J. Defieux, Herbert Lotman, Timothy S. Ramey and Stephen L. Waechter as directors continued after the annual meeting.
| Item 6. | Exhibits |
| 10.1 | Exclusive Distribution and Supply Agreement, dated as of May 4, 2005, by and between the Registrant and the DuPont Qualicon division of E.I. du Pont de Nemours. * † |
| 31.1 | Certifications of the Chief Executive Officer of Strategic Diagnostics Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934 |
| 31.2 | Certifications of the Chief Financial Officer of Strategic Diagnostics Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934 |
| 32.1 | Certification of the Chief Executive Officer of Strategic Diagnostics Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 |
| 32.2 | Certification of the Chief Financial Officer of Strategic Diagnostics Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 |
| * | Confidential treatment has been requested as to certain portions of this exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. |
| † | Previously filed. |
23
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| STRATEGIC DIAGNOSTICS INC. | |||
| Date: | March 16, 2006 | /s/ | Matthew H. Knight |
| Matthew H. Knight | |||
| President, Chief Executive Officer | |||
| (Principal Executive Officer) | |||
| Date: | March 16, 2006 | /s/ | Anthony J. Simonetta |
| Anthony J. Simonetta | |||
| Vice President – Finance and Chief Financial Officer | |||
| (Principal Financial and Accounting Officer) | |||
24